Silverstein Eye Centers
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (100.0%)Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
Phase 4
Completed
- Conditions
- Cataract Surgery
- Interventions
- Drug: Dexycu, 9% Intraocular Suspension
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Silverstein Eye Centers
- Target Recruit Count
- 15
- Registration Number
- NCT04316936
- Locations
- 🇺🇸
Silverstein Eye Centers, Kansas City, Missouri, United States
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Phase 4
Completed
- Conditions
- Treatment of Ocular Inflammation Associated With Cataract Surgery
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Silverstein Eye Centers
- Target Recruit Count
- 57
- Registration Number
- NCT03886779
News
No news found